Home Tags Bayer
"The approval of Vitrakvi is a testament to the relentless prioritization of biology in the drug development process," said Josh Bilenker, CEO of Loxo Oncology.
Stamford-based Loxo Oncology Inc has announced its completion of the rolling submission of a new drug application to the U.S. Food and Drug Administration for the TRK inhibitor treatment larotrectinib.
Loxo Oncology will receive an upfront payment of $400 million and will be eligible for $450 million in milestone payments upon regulatory approvals.
The pair have formed an alliance to establish the nation’s first-ever statewide radiation dose management repository.
Under the proposed swap, Boehringer will acquire Sanofi’s animal care subsidiary, while Sanofi will obtain Boehringer’s consumer health care business unit.